ERBB2 and gastric cancer: Park et al. [20] suggested using F2-FDG (18F) [2-fluoro-2-deoxyglucose] positron emission tomography (PET)/computed tomography (CT) for Her-2 gene screening for assessing the prognosis of patients with stage VI gastric cancer treated with trastuzumab.